A multi-center, open-lable, phase I trial of RG-101 in healthy volunteers and patients with hepatitis C virus infection with severe renal impairment

Trial Profile

A multi-center, open-lable, phase I trial of RG-101 in healthy volunteers and patients with hepatitis C virus infection with severe renal impairment

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs RG 101 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jun 2016 According to a Regulus Therapeutics media release, the company is on track to deliver follow-up results from this study at upcoming relevant scientific meetings.
    • 27 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to a Regulus Therapeutics media release.
    • 27 Jun 2016 According to a Regulus Therapeutics media release, the company plans to work with US FDA to seek the release of the clinical hold.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top